TABLE 51Spearman correlation between response criteria for the skin and arthritis components of the disease

Response measureTreatmenta
ArthritisSkinAdalimumab (n = 69)Placebo (n = 69)
PsARC (week 12)PASIc (week 12)0.49 (p < 0.0001)0.13 (p = 0.2969)
PsARC (week 24)PASIc (week 24)0.36 (p = 0.0023)0.26 (p = 0.304)
ACRb (week 12)PASIc (week 12)0.42 (p = 0.0004)0.23 (p = 0.0614)
ACRb (week 24)PASIc (week 24)0.38 (p = 0.0014)0.23 (p = 0.0612)
a

Correlation coefficient (significance).

b

< 20/20–50/50–70/70+.

c

< 50/50–75/75–90/90+.

From: Appendix 6, Clarifications from manufacturers

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.